A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
The purpose of this study is to provide remdesivir (RDV) to participants with moderate COVID-19.
Participants will be randomly assigned to receive either continued SOC therapy together with intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-5, or continued SOC therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-10.
- IRB Number: 2003894138
- Research Study Identifier: 2003894138
- Principal Investigator: Samir Gupta, MD
Recruitment StatusEnrolling By Invitation
If you need help finding a study or have any questions, please contact us at email@example.com or by phone at (888) 264-0005.